QS Investors LLC Has $4.82 Million Stake in Catalent (CTLT)

QS Investors LLC grew its position in shares of Catalent (NYSE:CTLT) by 67.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 117,335 shares of the company’s stock after purchasing an additional 47,366 shares during the period. QS Investors LLC owned about 0.09% of Catalent worth $4,820,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the business. Meeder Asset Management Inc. grew its holdings in shares of Catalent by 14.8% during the 4th quarter. Meeder Asset Management Inc. now owns 9,445 shares of the company’s stock worth $388,000 after acquiring an additional 1,218 shares during the period. First Bank & Trust lifted its position in Catalent by 54.2% in the 4th quarter. First Bank & Trust now owns 3,764 shares of the company’s stock valued at $155,000 after acquiring an additional 1,323 shares in the last quarter. SG Americas Securities LLC lifted its position in Catalent by 4.1% in the 4th quarter. SG Americas Securities LLC now owns 39,984 shares of the company’s stock valued at $1,643,000 after acquiring an additional 1,579 shares in the last quarter. First Trust Advisors LP lifted its position in Catalent by 1.5% in the 3rd quarter. First Trust Advisors LP now owns 109,815 shares of the company’s stock valued at $4,384,000 after acquiring an additional 1,597 shares in the last quarter. Finally, Strs Ohio lifted its position in Catalent by 7.4% in the 4th quarter. Strs Ohio now owns 23,300 shares of the company’s stock valued at $957,000 after acquiring an additional 1,600 shares in the last quarter. 99.89% of the stock is owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

In other Catalent news, SVP William Downie sold 9,082 shares of the company’s stock in a transaction dated Thursday, March 8th. The shares were sold at an average price of $41.80, for a total value of $379,627.60. Following the completion of the transaction, the senior vice president now owns 46,986 shares in the company, valued at $1,964,014.80. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 1.70% of the company’s stock.

Shares of CTLT traded down $0.74 during trading hours on Friday, reaching $39.00. 677,182 shares of the company traded hands, compared to its average volume of 766,169. The firm has a market capitalization of $5,298.09, a PE ratio of 28.89, a price-to-earnings-growth ratio of 2.30 and a beta of 1.53. Catalent has a 12-month low of $27.48 and a 12-month high of $47.87. The company has a debt-to-equity ratio of 2.66, a current ratio of 2.22 and a quick ratio of 1.78.

Catalent (NYSE:CTLT) last posted its earnings results on Monday, February 5th. The company reported $0.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.10. The company had revenue of $606.30 million during the quarter, compared to the consensus estimate of $565.05 million. Catalent had a net margin of 3.03% and a return on equity of 23.85%. The firm’s quarterly revenue was up 25.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.27 earnings per share. research analysts anticipate that Catalent will post 1.52 EPS for the current fiscal year.

Several equities analysts have recently weighed in on the company. Goldman Sachs started coverage on Catalent in a report on Wednesday, January 24th. They set a “buy” rating and a $50.00 price target on the stock. Royal Bank of Canada set a $48.00 price target on Catalent and gave the stock a “buy” rating in a research note on Monday, February 5th. Stephens lowered Catalent from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, February 6th. Zacks Investment Research upgraded Catalent from a “hold” rating to a “buy” rating and set a $48.00 price objective for the company in a research report on Wednesday, January 17th. Finally, Bank of America lifted their price target on Catalent from $47.00 to $49.00 and gave the stock a “buy” rating in a research report on Tuesday, February 6th. Five analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $45.75.

ILLEGAL ACTIVITY NOTICE: This report was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/07/qs-investors-llc-boosts-stake-in-catalent-inc-ctlt.html.

Catalent Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.

Institutional Ownership by Quarter for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply